IXICO plc IXICO contract with new large global pharma (8322H)
08 December 2020 - 6:00PM
UK Regulatory
TIDMIXI
RNS Number : 8322H
IXICO plc
08 December 2020
IXICO plc
("IXICO" or the "Company")
IXICO contract with new large global pharma
IXICO selected by new large global pharma for orphan drug
clinical trial
IXICO plc (AIM: IXI), the AI data analytics company delivering
insights in neuroscience, has secured a contract for neuroimaging
solutions with a new, large global pharmaceutical company. The
Phase IIB trial will investigate an orphan drug designated clinical
asset for the treatment of Huntington's disease.
Huntington's disease (HD) is a progressive and devastating
neurodegenerative disorder for which no disease-modifying therapies
currently exist. Orphan drug designations help biopharmaceutical
sponsors undertake valuable investigations and develop treatments
for rare and complex conditions such as HD. Since its inception in
2004, IXICO has had an extensive track record of delivering
innovative neuroimaging solutions to support clients in optimising
their pipelines for rare diseases.
This contract was included in management's expectations of
performance for the current financial year but adds to the
Company's strong order book.
Lammert Albers, Chief Commercial Officer of IXICO, commented:
"We are delighted to be chosen to take part in this HD study to
advance development of promising medical treatments for this
devastating rare disease. This contract and new partnership will
further endorse our breakthrough neuroimaging technologies with
large pharma sponsors across the full spectrum of the drug
development pathway."
For further information please contact:
IXICO plc +44 (0)20 3763 7498
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate
Finance)
Michael F Johnson / Russell Kerr
(Sales
Walbrook PR Ltd +44 (0)20 7933 8780
Paul McManus / Lianne Cawthorne IXICO@walbrookpr.com
/
Alice Woodings
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our
purpose is to advance medicine and human health by turning data
into clinically meaningful information, providing valuable new
insights in neuroscience and our goal is to be a leading proponent
of artificial intelligence in medical image analysis. We will
achieve this by developing and deploying breakthrough data
analytics, at scale, through our remote access technology platform,
to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for our pharmaceutical
clients.
More information is available on www.IXICO.com and follow us on Twitter @IxicOplc
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTFSEFWWESSELE
(END) Dow Jones Newswires
December 08, 2020 02:00 ET (07:00 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024
Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024